MedTrace Logo

Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy

NCT06623903 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 112

Last updated 2024-10-02

No results posted yet for this study

Summary

This clinical trial aims to investigate early metabolic health changes in early breast cancer patients that initiate antihormone therapy. Furthermore, how these changes are affected by estrogen level, treatment type, and patient characteristics. The hypothesis is, that initiation of antihormone therapy for early breast cancer patients is associated with an early deterioration in metabolic health after 3 months. This includes increased BMI (Body Mass Index), waist- and hip circumference, blood pressure, blood sugars, and lipids compared to when the patients initiate antihormone therapy. Concurrently, estradiol levels are expected to decrease. An estimated 112 patients initiating antihormone therapy at the Dept. of Oncology, Aarhus University Hospital (AUH) will be included in the study over 6 months from autumn 2024. Patients will have a metabolic screening on the day of initiating antihormone therapy and at 3-month antihormone treatment follow-up. The two metabolic screenings each consists of biometric measurements and a blood sample.

Conditions

  • Early Breast Cancer
  • Metabolic Health
  • Estrogen Receptor Positive Breast Cancer

Sponsors & Collaborators

  • Danish Cancer Society

    collaborator OTHER

  • Aarhus University Hospital

    lead OTHER

Principal Investigators

  • Signe Borgquist, Clinical Chair Professor, Ph.D · Aarhus University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06623903 on ClinicalTrials.gov